Skip to main content
. 2022 Jul 30;14(8):1589. doi: 10.3390/pharmaceutics14081589

Figure 3.

Figure 3

Schematic of EGCG for cancer immunotherapy. (A) EGCG is the active compound derived from green tea. (B) Schematic of the mechanisms of EGCG for the inhibition of the PD-1/PD-L1 axis. (C) Downregulation of epidermal growth factor (EGF) and IFN-γ-induced PD-L1 protein in Lu99 cells after EGCG treatment. (D) Downregulation of p-STAT1 and STAT1 in B16F10 cells after EGCG treatment. (E) Immunofluorescence images of tumor tissue sections stained with CD8 (green) and DAPI (blue). (F) Immunofluorescence images of tumor tissue sections stained with CD8 (green), PD-L1 (red), and DAPI (blue). Reprinted with permission from Ref. [90]. Copyright 2018, copyright MDPI. Reprinted with permission from ref. [91]. Copyright 2021, copyright MDPI.